Trial intelligence / Profile preview

Double-blind Phase 3 study of tocilizumab in rheumatoid arthritis

jRCT2080220018Phase 3

Sponsor
Chugai Pharmaceutical Co., Ltd.
Start
Sep 2005
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Chugai Pharmaceutical Co., Ltd.

02

Drugs

tocilizumab
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on jRCT2080220018.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080220018.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call